Loading...
01/11 03:09
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call indicates strong financial performance with a 12% increase in Q1 sales, improved gross margins, and an increase in organic sales growth guidance from 10% to 13%. Despite some concerns in the Q&A about Xenosure in China and vague responses regarding share buybacks, the overall sentiment is positive due to the increased guidance and strategic moves like exiting the declining Elutia distribution. The market cap suggests moderate volatility, leading to a positive stock price prediction (2% to 8%) over the next two weeks.
Q1 Sales $45.5 million, up 12% year-over-year, driven by strong performance in graphs (up 17%) and carotid shunts (up 14%).
Gross Margin 69.2%, a 60 basis point increase year-over-year, primarily due to higher average selling prices (ASPs) and lower inventory scrap, offset by a negative product mix impact.
Operating Expenses $28.8 million, an increase of 16% year-over-year, largely due to higher compensation expenses from adding 21 sales professionals and increased non-compensation sales-related expenses.
Operating Income $12.6 million, up 6% year-over-year, resulting in an operating margin of 21%.
Fully Diluted EPS $0.48, up 10% year-over-year.
Cash and Securities $302.5 million, an increase of $2.8 million in the quarter.
Cash from Operations $9 million generated in the quarter.
Dividends Paid $4.5 million to shareholders.
Final Deferred Payment $1.4 million related to the 2019 cardio cell acquisition.
Sales Guidance Increased to $245 million from $239 million, reflecting strong sales momentum and regulatory progress.
Organic Sales Growth Guidance Increased to 13% from 10%, driven by strong sales performance.
Gross Margin Guidance Updated to 69.6% for the full year.
Operating Income Guidance Updated to $57.7 million for the full year.
Diluted EPS Guidance Midpoint updated to $2.16 for the full year.
New Product Launch: Received MDR CE mark for autographs, with European launch expected to begin shortly. Autographed biologic craft was the largest US product in 2024 with $37 million in sales.
International Sales: International sales of autographs reached $180,000 in Q1. Expecting approvals in Australia, Canada, Singapore, and Korea by H1 2026.
Market Expansion: Opened new sales offices in Switzerland and Portugal, with direct sales expected to begin in both countries.
Sales Growth: Q1 sales growth of 13% organic and 12% reported, with significant growth in EMEA (18%) and the Americas (11%).
Operational Efficiency: Increased sales force to 164 reps, targeting 170 by year-end. New production facility in New Jersey is capable of meeting increased demand.
Cost Management: Wound down porcelain patch distribution agreement with Elutia to focus on own biologics, expected to improve organic growth rate and gross margin.
Strategic Shift: Increased 2025 sales guidance to $245 million from $239 million, reflecting strong sales momentum and regulatory progress.
Tariff Management: Company is well-positioned regarding tariffs, with 100% US manufacturing and limited foreign supplier costs.
Regulatory Issues: The company is awaiting approvals for its RestoreFlow allograft in Ireland or Germany, which are necessary for expedited approvals in other European countries. Allografts require country-by-country approval, which can delay market entry.
Supply Chain Challenges: Approximately 25% of the cost of goods sold is for raw materials and components sourced from foreign suppliers, primarily Australia. The company faces potential retaliatory tariffs impacting international sales, particularly in China.
Economic Factors: The company anticipates that tariffs could impact costs, specifically noting that Chinese import tariffs will increase costs by approximately $825,000 annually. However, they plan to implement price increases to offset these costs.
Competitive Pressures: Despite operating in low rivalry markets, the company acknowledges the potential for price increases to mitigate the impact of tariffs and maintain competitive positioning.
Discontinuation of Distribution Agreement: The amicable winding down of the porcelain patch distribution agreement with Elutia may impact sales, but is expected to improve organic growth rates and gross margins.
Sales Force Growth: LeMaitre currently has 164 reps on payroll, targeting 170 by year-end. They also employ 34 sales managers, up from 31 in the last earnings call.
International Sales Offices: New regional sales manager in Switzerland overseeing seven reps, with direct sales expected to start in August. Direct sales in Portugal began on May 1.
MDR CE Mark for Autographs: Received MDR CE mark for autographs, with European launch expected soon. Autographs generated $37 million in US sales in 2024.
RestoreFlow Allograft Approval: Anticipating at least one RestoreFlow allograft approval in 2025 from Ireland or Germany, which would expedite approvals in other European countries.
2025 Sales Guidance: Increased to $245 million from $239 million, with organic sales guidance raised to 13% from 10%.
Gross Margin Guidance: Expected gross margin of 69.6% for 2025.
Operating Income Guidance: Projected operating income of $57.7 million for 2025.
Earnings Per Share Guidance: Midpoint guide on diluted earnings per share of $2.16 for 2025.
Dividends Paid: $4.5 million paid to shareholders in Q1 2025.
Share Repurchase Program: None
The company has raised its full-year revenue guidance and EPS, indicating strong financial performance. Despite some management ambiguity on future metrics, the overall sentiment is positive with strategic growth plans, including Artegraft and XenoSure expansion, and a robust sales force strategy. The market cap suggests moderate reaction, predicting a 2-8% stock price increase.
The earnings call reflects a positive outlook with increased sales guidance, strong international growth, and optimistic product feedback. Despite minor setbacks, such as not reaching the sales rep target and uncertainty in price hikes, the overall sentiment is bolstered by strategic international expansions and improved margins. The market cap suggests a moderate reaction, aligning with a 'Positive' sentiment.
The earnings call indicates strong financial performance with a 12% increase in Q1 sales, improved gross margins, and an increase in organic sales growth guidance from 10% to 13%. Despite some concerns in the Q&A about Xenosure in China and vague responses regarding share buybacks, the overall sentiment is positive due to the increased guidance and strategic moves like exiting the declining Elutia distribution. The market cap suggests moderate volatility, leading to a positive stock price prediction (2% to 8%) over the next two weeks.
The earnings call indicates strong financial performance with significant sales and EPS growth, a 25% dividend increase, and improved margins. While there are potential challenges in new markets and supply chain complexities, the guidance remains optimistic, expecting 10% organic growth. The Q&A section reveals management's cautious optimism and strategic hiring plans, although some answers were vague. Given the company's market cap, the positive financial metrics and shareholder returns suggest a likely positive stock price movement over the next two weeks.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
